

Benjamin K Hodnett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5418791/publications.pdf>

Version: 2024-02-01

58
papers

2,085
citations

186265

28
h-index

233421

45
g-index

59
all docs

59
docs citations

59
times ranked

2289
citing authors

#	ARTICLE	IF	CITATIONS
1	Studying the impact of the pre-exponential factor on templated nucleation. <i>Faraday Discussions</i> , 2022, 235, 199-218.	3.2	2
2	The role of the pre-exponential factor in determining the kinetic selection of polymorphs during solution crystallization of organic compounds. <i>CrystEngComm</i> , 2022, 24, 3088-3095.	2.6	1
3	Effects of structurally related impurities on the crystal growth of curcumin spherulites. <i>CrystEngComm</i> , 2022, 24, 5156-5169.	2.6	2
4	Extended Lifetime of Molecules Adsorbed onto Excipients Drives Nucleation in Heterogeneous Crystallization. <i>Crystal Growth and Design</i> , 2021, 21, 2101-2112.	3.0	4
5	Preparation, stabilisation, isolation and tableting of valsartan nanoparticles using a semi-continuous carrier particle mediated process. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120199.	5.2	4
6	Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 193, 111120.	5.0	28
7	Growth kinetics of curcumin form I. <i>CrystEngComm</i> , 2020, 22, 3505-3518.	2.6	10
8	Crystal Growth Kinetics of Pharmaceutical Compounds. <i>Crystal Growth and Design</i> , 2020, 20, 7626-7639.	3.0	13
9	Thermodynamic vs. Kinetic Basis for Polymorph Selection. <i>Processes</i> , 2019, 7, 272.	2.8	4
10	Carrier particle mediated stabilization and isolation of valsartan nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 554-563.	5.0	14
11	Heterogeneous Crystallization of Fenofibrate onto Pharmaceutical Excipients. <i>Crystal Growth and Design</i> , 2018, 18, 2151-2164.	3.0	14
12	Experimental Study on the Influence of Excipients on the Heterogeneous Crystallization and Dissolution Properties of an Active Pharmaceutical Ingredient. <i>Crystal Growth and Design</i> , 2018, 18, 338-350.	3.0	18
13	Dependence of Heterogeneous Nucleation on Hydrogen Bonding Lifetime and Complementarity. <i>Crystal Growth and Design</i> , 2018, 18, 7158-7172.	3.0	19
14	A basis for the kinetic selection of polymorphs during solution crystallization of organic compounds. <i>CrystEngComm</i> , 2018, 20, 5551-5561.	2.6	14
15	Influence of Structurally Related Impurities on the Crystal Nucleation of Curcumin. <i>Crystal Growth and Design</i> , 2018, 18, 4715-4723.	3.0	33
16	The heterogeneous crystallization of a novel solvate of clozapine base in the presence of excipients. <i>CrystEngComm</i> , 2018, 20, 4370-4382.	2.6	13
17	Influence of Process Parameters on the Heterogeneous Nucleation of Active Pharmaceutical Ingredients onto Excipients. <i>Organic Process Research and Development</i> , 2017, 21, 559-570.	2.7	13
18	Extraction and Purification of Curcuminoids from Crude Curcumin by a Combination of Crystallization and Chromatography. <i>Organic Process Research and Development</i> , 2017, 21, 821-826.	2.7	36

#	ARTICLE	IF	CITATIONS
19	Process Parameters in the Purification of Curcumin by Cooling Crystallization. <i>Organic Process Research and Development</i> , 2016, 20, 1593-1602.	2.7	35
20	Demonstrating the Influence of Solvent Choice and Crystallization Conditions on Phenacetin Crystal Habit and Particle Size Distribution. <i>Organic Process Research and Development</i> , 2015, 19, 1826-1836.	2.7	35
21	Achieving Continuous Manufacturing: Technologies and Approaches for Synthesis, Workup, and Isolation of Drug Substance May 2014. 2014 Continuous Manufacturing Symposium. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 781-791.	3.3	129
22	Solution-Mediated Polymorphic Transformation: Form II to Form III Piracetam in Organic Solvents. <i>Crystal Growth and Design</i> , 2014, 14, 3967-3974.	3.0	46
23	Solution-Mediated Polymorphic Transformation of FV Sulphathiazole. <i>Crystal Growth and Design</i> , 2014, 14, 3466-3471.	3.0	18
24	Solid-State Transformations of Sulfathiazole Polymorphs: The Effects of Milling and Humidity. <i>Crystal Growth and Design</i> , 2013, 13, 3404-3413.	3.0	45
25	Investigation into the Mechanism of Solution-Mediated Transformation from FI to FIII Carbamazepine: The Role of Dissolution and the Interaction between Polymorph Surfaces. <i>Crystal Growth and Design</i> , 2013, 13, 1861-1871.	3.0	41
26	Measuring the Solubility of a Quickly Transforming Metastable Polymorph of Carbamazepine. <i>Organic Process Research and Development</i> , 2013, 17, 512-518.	2.7	27
27	Investigation of the Solid-State Polymorphic Transformations of Piracetam. <i>Crystal Growth and Design</i> , 2012, 12, 6223-6233.	3.0	37
28	Understanding the <i>p</i> -Toluenesulfonamide/Triphenylphosphine Oxide Crystal Chemistry: A New 1:1 Cocrystal and Ternary Phase Diagram. <i>Crystal Growth and Design</i> , 2012, 12, 869-875.	3.0	26
29	Solubility of the Metastable Polymorph of Piracetam (Form II) in a Range of Solvents. <i>Journal of Chemical & Engineering Data</i> , 2012, 57, 3525-3531.	1.9	35
30	Solution Mediated Polymorphic Transformation: Form II to Form III Piracetam in Ethanol. <i>Crystal Growth and Design</i> , 2012, 12, 6151-6157.	3.0	48
31	Examining Solution and Solid State Composition for the Solution-Mediated Polymorphic Transformation of Carbamazepine and Piracetam. <i>Crystal Growth and Design</i> , 2012, 12, 1925-1932.	3.0	81
32	Relative Stabilities of the Five Polymorphs of Sulfathiazole. <i>Crystal Growth and Design</i> , 2012, 12, 2825-2835.	3.0	51
33	A comparative study of the use of powder X-ray diffraction, Raman and near infrared spectroscopy for quantification of binary polymorphic mixtures of piracetam. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 63, 80-86.	2.8	62
34	Epitaxial growth of polymorphic systems: The case of sulfathiazole. <i>CrystEngComm</i> , 2011, 13, 5903.	2.6	16
35	Solubility of Form III Piracetam in a Range of Solvents. <i>Journal of Chemical & Engineering Data</i> , 2010, 55, 5314-5318.	1.9	59
36	Oxidation of ABTS by Silicate-Immobilized Cytochrome c in Nonaqueous Solutions. <i>Biotechnology Progress</i> , 2008, 19, 1238-1243.	2.6	28

#	ARTICLE	IF	CITATIONS
37	Proteins in Mesoporous Silicates. ACS Symposium Series, 2008, , 49-60.	0.5	5
38	Influence of pH and ionic strength on the adsorption, leaching and activity of myoglobin immobilized onto ordered mesoporous silicates. Journal of Molecular Catalysis B: Enzymatic, 2007, 49, 61-68.	1.8	89
39	Characteristics of a Mesoporous Silicate Immobilized Trypsin Bioreactor in Organic Media. Biotechnology Progress, 2006, 22, 1125-1131.	2.6	30
40	Phase development and morphology during the thermal treatment of VOHPO ₄ ·0.5H ₂ O. Applied Catalysis A: General, 2005, 285, 36-42.	4.3	9
41	Methodology for the Immobilization of Enzymes onto Mesoporous Materials. Journal of Physical Chemistry B, 2005, 109, 19496-19506.	2.6	176
42	Effect of Amino Acid Additives on the Crystallization of l-Glutamic Acid. Crystal Growth and Design, 2005, 5, 593-597.	3.0	54
43	Surface species during the crystallization of VOHPO ₄ ·0.5H ₂ O. Journal of Catalysis, 2004, 227, 270-281.	6.2	40
44	In situ X-ray diffraction studies of the crystallization of VOHPO ₄ ·0.5H ₂ O. Catalysis Today, 2004, 91-92, 185-189.	4.4	6
45	Adsorption and Activity of Proteins onto Mesoporous Silica. Catalysis Letters, 2003, 85, 19-23.	2.6	87
46	Stability of MCM-48 in aqueous solution as a function of pH. Microporous and Mesoporous Materials, 2003, 63, 53-57.	4.4	36
47	Crystallisation of VOHPO ₄ ·0.5H ₂ O in the presence of a surfactant. Applied Catalysis A: General, 2003, 251, 327-335.	4.3	11
48	Crystallisation of VOHPO ₄ ·0.5H ₂ O. Applied Catalysis A: General, 2003, 253, 409-416.	4.3	9
49	Inclusion of the Stable Form of a Polymorph within Crystals of Its Metastable Form. Crystal Growth and Design, 2003, 3, 869-872.	3.0	32
50	Utilisation of a Mesoporous Silicate Material for the Removal of Quaternary Ammonium Hydroxides (QAHs) from Aqueous Solution. Adsorption Science and Technology, 2002, 20, 261-267.	3.2	1
51	Mechanistic and Structural Features of Protein Adsorption onto Mesoporous Silicates. Journal of Physical Chemistry B, 2002, 106, 7340-7347.	2.6	256
52	An Investigation into the Adsorption Characteristics of Grafted Mesoporous Silicates for the Removal of Tetramethyl Ammonium Hydroxide from Aqueous Solution. Adsorption Science and Technology, 2002, 20, 787-796.	3.2	2
53	Preparation and use of a mesoporous silicate material for the removal of tetramethyl ammonium hydroxide (TMAH) from aqueous solution. Journal of Chemical Technology and Biotechnology, 2001, 76, 1216-1222.	3.2	37
54	In-situ epoxidation using dioxiranes: evaluation of reactivity and selectivity. Journal of Chemical Technology and Biotechnology, 1998, 72, 60-66.	3.2	4

#	ARTICLE	IF	CITATIONS
55	Recovery of chromium from tannery effluents using a redox-adsorption approach. Journal of Chemical Technology and Biotechnology, 1995, 62, 30-37.	3.2	34
56	Influence of metal-support interactions on the stability of Ni/SiO ₂ catalysts during cyclic oxidation-reduction treatments. Journal of the Chemical Society Faraday Transactions I, 1984, 80, 3209.	1.0	33
57	Reactions involving electron transfer at semiconductor surfaces. Part 12. Nature and origins of photoactivity on oxides of 3d transition metals for elimination reactions of secondary alcohols. Journal of the Chemical Society Faraday Transactions I, 1982, 78, 3297.	1.0	11
58	Kinetic studies of secondary alcohol photo-oxidation on ZnO and TiO ₂ at 348 K studied by gas-chromatographic analysis. Journal of the Chemical Society Faraday Transactions I, 1981, 77, 2777.	1.0	62